OFFICIAL REPORTS ON PHARMACOVIGILANCE PROGRAMS - 29 July 2021

CANADA

• As of 23 July 2021, 47,106,106 doses of COVID-19 vaccines of Pfizer-BioNTech, Moderna, AstraZeneca, and Covishield (manufactured by the Serum Institute of India) had been administered.
• A total of 10,807 individual reports of one or more adverse events (0.023% of doses administered) were received. Of these, 2,682 involved serious events (0.006% of doses administered).
• Following is information on these reported adverse events following immunization (AEFI), by vaccine and type of event:

• A total of 28,981 AEFI were reported (10,807 involving one or more events). The most frequently reported non-serious adverse events were injection-site reactions, paresthesia, itching, hives, headache, hypoesthesia, and nausea. There were 137 reported cases of anaphylaxis, of which 113 were associated with the Pfizer-BioNTech vaccine (0.36 per 100,000 doses administered) and 24 with the Moderna vaccine (0.21 per 100,000 doses administered).
• As of 23 July, there were 67 reported cases of thrombosis with thrombocytopenia syndrome (TTS), of which 56 involved individuals who had received the Covishield/AstraZeneca vaccine, 9 who had received the Pfizer-BioNTech vaccine, and 2 who had received the Moderna vaccine. In cases associated with the Covishield/AstraZeneca vaccine, onset of symptoms was between one and 34 days after vaccination. Of these cases, 23 were women (ages 44 to 88), 32 were men (ages 34 to 73), and in one case the sex of the person was not identified.
• A total of 162 post-vaccination deaths were reported. Following a medical review, it was determined that 66 of the deaths were not linked to administration of the COVID-19 vaccine; 33 are still under investigation; 6 (cases of TTS) were considered to be potentially attributable to vaccination; and in 57 cases the cause of death could not be determined due to insufficient information.
• As of 23 July, 230 cases of myocarditis/pericarditis had been reported; below is a list of the vaccines administered in these cases:

• As of 23 July, one case of capillary leak syndrome had been reported following administration of the first dose of the Covishield/AstraZeneca vaccine.
• In addition, 53 cases of Guillain-Barré Syndrome (GBS) were reported, of which 25 occurred after administration of the Covishield/AstraZeneca vaccine, 20 after administration of the Pfizer-BioNTech vaccine, and 8 following administration of the Moderna vaccine.

Source: https://health-infobase.canada.ca/covid-19/vaccine-safety/

CHILE

• According to official sources, between 24 December 2020 and 14 May 2021, 16,571,766 doses of COVID-19 vaccines were administered in Chile: 13,862,155 doses (83.6%) of the CoronaVac vaccine, 2,619,095 doses (15.8%) of the Pfizer-BioNTech vaccine, and 90,516 doses (0.5%) of the AstraZeneca vaccine.
• In that period, a total of 8,855 AEFI were reported:

• Of the 8,855 reports, 6,683 (75.5%) involved women, 2,101 (23.7%) involved men, and in 72 cases (0.8%) the sex of the person was not identified.
• Of these reported events, 57.7% involved adults between the ages of 16 and 39.
• For the three vaccines, the most frequently reported clinical manifestations included: pain at the injection site, headache, fever, malaise, and myalgia.
• With regard to adverse events of special interest (AESI) associated with the Pfizer-BioNTech vaccine, reports included 37 cases of anaphylaxis, 13 cases of seizures, 9 of Bell's palsy, 7 of thromboembolic events, and 3 of GBS. For the CoronaVac vaccine, there were 121 reported cases of anaphylaxis, 36 of seizures, 28 of Bell's palsy, 16 of thromboembolic events, and 4 of GBS.

Source: https://www.ispch.cl/wp-content/uploads/2021/07/Quinto-informe-ESAVI-asociados-a-la-administraci%C3%B3n-de-la-vacuna-SARS-CoV-2-en-Chile.pdf

COSTA RICA

• As of 4 July 2021, the Directorate of Epidemiological Sub-Surveillance, of the Costa Rican Social Security Fund, reported that it had administered 2,878,760 doses of COVID-19 vaccines.
• As of 4 July 2021, 4,597 AEFI associated with administration of the Pfizer-BioNTech vaccine had been reported, while there were 2,197 reports of AEFI associated with the AstraZeneca vaccine.
• From the start of the vaccination program to 4 July, there were 24 reported events that were classified as serious, all of which were associated with the Pfizer-BioNTech vaccine. Of these, 16 individuals have recovered or are in the process of recovering and 8 died.

Source: https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2145-vacunados-contra-covid-19-reportan-sintomas-leves-y-poco-frecuentes-despues-de-la-inmunizacion

PARAGUAY

• Between 22 February 2021 and 16 July 2021, Paraguay's Immunization Program received 1,684 reports of adverse events following administration of COVID-19 vaccines of Sputnik V, Sinovac (CoronaVac), Sinopharm, AstraZeneca, Covaxin, Hayat-Vax,* and Moderna, or 0.1% of doses administered, of which 166 cases are still under investigation.
• Of these reported AEFI, 74.2% (1,251) involved women and 25.7% (433) involved men.
• The most frequently reported clinical manifestations of AEFI were myalgias (72%), fever (61%), headache (61%), injection-site pain (58%), and fatigue (50%). Most reports involved more than one clinical manifestation.
• Notably, the reporting rate of AEFI for the Coronavac vaccine was 915.25 per 100,000 doses administered, while the rates for Sinopharm, AstraZeneca, and Sputnik V were 612.87, 237.13, and 99.31, respectively; the AEFI reporting rate for the COVAXIN vaccine was 73.04 per 100,000 doses administered.
  • Hayat-Vax is a vaccine that is the result of a joint project between Sinopharm CNBG and G42, of the United Arab Emirates, in Abu Dhabi.

Source: http://pai.mspbs.gov.py/article/vigilancia-esavi